NTLA
Intellia Therapeutics
Stock NASDAQ – Stock Market Prices, News & Analysis
Intellia Therapeutics is a biotechnology company dedicated to developing therapies using CRISPR-Cas9 technology for genome editing.
Intellia Therapeutics
NTLA
Intellia Therapeutics is a biotechnology company dedicated to developing therapies using CRISPR-Cas9 technology for genome editing.
Price history of Intellia Therapeutics
Price history of Intellia Therapeutics
Performance & Momentum
Strategic Analysis
Intellia Therapeutics • 2026
Intellia Therapeutics positions itself as a key player in the biotechnology sector by developing innovative therapies based on CRISPR-Cas9 genomic editing technology. Its business model focuses on leveraging the therapeutic potential of this groundbreaking technology, targeting genetic diseases with high medical need.
Strengths
- Advanced mastery of CRISPR technology, a major innovation in genomic engineering
- Strong research and development orientation with strategic partnerships
- Significant clinical potential in rare and severe indications
Weaknesses
- Pre-commercial financial profile with no recurring revenue
- Historically high volatility related to clinical advancements and regulatory uncertainties
Momentum
Recent momentum shows a moderate recovery after a period marked by long-term degraded performance, reflecting a resurgence of investor interest in line with expected clinical progress. This dynamic calls for strategic vigilance regarding the evolution of results and development announcements.
Similar stocks to Intellia Therapeutics
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
